Pasithea Therapeutics Corp. (KTTA)
Nasdaq · Healthcare · Biotechnology
$0.4549−4.43%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $15.2M
- 52-week range
- $0.281 – $2.06
- 52-week change
- −41.38%
- EPS (trailing)
- −$1.59
Fiscal year to Dec 2025
- Net income
- −$20.4M
- Diluted EPS
- −$2.91
From the company’s annual report on SEC EDGAR.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Headquarters: Miami Beach, United States · 5 employees · pasithea.com